Today, the molecular diagnostics industry is moving forward rapidly to build
the biomarker based tools, assays, alliances, process improvements, and synergies
with anatomic pathology in its quest to dramatically reduce cancer mortality
rates and detect cancers at a much early stage.
This new report from Washington G-2 Reports provides insight and expert advice
on how these developments can be harnessed to aid the lab in mastering a broad
range of cancer detection tools, building test menus and developing the business
models and methods for reimbursement that will dictate success in this market.
Washington G-2 Reports’ combination of experience in and working knowledge
of molecular diagnostic laboratories and its nationwide network of industry
and financial contacts, plus its many years of coverage of this market from
a reporting perspective, make it uniquely suited to prepare this report.
With it, you’ll get insight and expert advice to help your lab master a broad
range of cancer detection tools, build test menus and develop the business models
and methods for reimbursement that will dictate success in this market.
Inside, you'll find:
- Novel applications and technologies with respect to detecting human cancers
- How to optimize efficiency in the diagnostic setting
- Alliance management for the onco-molecular diagnostics lab
- Collaborative telemedicine: Synergy between molecular and anatomic pathology
in diagnosing cancer
- Scientific challenges and ethical questions in testing for breast cancer
in the era of genomic medicine
- Novel biomarkers show promise for improved cancer screening
- Coding and reimbursement for molecular diagnostics
- Clinical validation and regulation of real-time QPCR test systems for the
onco-molecular diagnostic market
- Integromic approach to cancer biomarkers, genomics, proteomics, and bioinformatics
- And much more
In developing this report, Washington G-2 Reports relied on contributions and
presentations from over a dozen onco-molecular experts, in addition the editors
at Washington G-2 Reports conducted dozens of interviews with molecular lab
physicians, experts and managers.
List
of Experts and Contributors:
--Richard Bender, M.D., medical director, hematology/oncology, Quest Nichols
Brian Dapp, implementation specialist, OpEx Inc.
--Ed Dougherty, senior vice president, B&D Consulting
--George Gorodeski, M.D., Ph.D., professor, Departments of Reproductive Biology,
Oncology, and Physiology and Biophysics, Case Western Reserve University, and
Department of Obstetrics & Gynecology, University Hospital CASE Medical
Center
--Wayne Grody, M.D., Ph.D., professor, Divisions of Medical Genetics &
Molecular Pathology, David Geffen School of Medicine at UCLA
--Paul Landauer, senior director, global commercial planning and development,
Abbott Molecular Inc.
--Jorge A. Leon, Ph.D., president, Leomics Associates Consulting
--Dawn Maghakian, MS, MP(ASCP), CLSp(MB), supervisor, Biochemical Genetics
& Molecular Pathology Clinical Laboratories, Stanford Hospital & Clinics,
Stanford University Medical Center
--Ronald McGlennen, M.D., president and medical director, Access Genetics
--Bruce K. Patterson, M.D., medical director of virology, pathology & laboratory
medicine, Stanford University School of Medicine
--Bruce Quinn, M.D., contractor medical director, California Medicare Part
B, NHIC Corp.
--Colette F. Saccomanno, Ph.D., director of client research, DrugLogic®
Inc.
Gordon Schatz, Esq., partner, Reed Smith LLP
--Iris Schrijver, M.D., director, Molecular Pathology Laboratory, Stanford
University Medical Center
--Gregory Tsongalis, MHS, Ph.D., director of molecular pathology at Dartmouth
Medical School
--Diana Voorhees, MA, CLS, MT, SH, CLCP, president/principal, DV & Associates
Inc.
--John Weinstein, M.D., Ph.D., head, Genomics & Bioinformatics Group, LMP,
CCR, National Cancer Institute, Laboratory of Molecular Pharmacology
Preview this report's Table of Contents and Preface.
